Literature DB >> 11342623

Recombinant allergens with reduced allergenicity but retaining immunogenicity of the natural allergens: hybrids of yellow jacket and paper wasp venom allergen antigen 5s.

T P King1, S Y Jim, R I Monsalve, A Kagey-Sobotka, L M Lichtenstein, M D Spangfort.   

Abstract

The homologous venom allergen Ag 5s from the yellow jacket (Vespula vulgaris) and paper wasp (Polistes annularis) have 59% sequence identity of their respective 204 and 205 amino acid residues, and they have low degrees of antigenic cross-reactivity in insect allergic patients and in animal models. Hybrids containing different segments of these two vespid Ag 5s were expressed in yeast. Circular dichroism spectroscopy suggests the hybrids to have the secondary structure of natural Ag 5. Inhibition ELISA with human and murine Abs suggests the hybrids to have the discontinuous B cell epitopes of the natural Ag 5 but with an altered epitope density. The hybrids were immunogenic in mice for B and T cell responses to both Ag 5s. The N-terminal region of Ag 5 was found to contain its dominant B cell epitope(s). Hybrids containing 10-49 residues of yellow jacket Ag 5 showed 100- to 3000-fold reduction in allergenicity when tested by histamine release assay with basophils of yellow jacket-sensitive patients. Our findings suggest that hybrids represent a useful approach to map the discontinuous B cell epitope-containing regions of proteins. They also suggest that Ag 5 hybrids may be useful immunotherapeutic reagents in man.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11342623     DOI: 10.4049/jimmunol.166.10.6057

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

Review 1.  Hymenoptera venom allergens.

Authors:  Donald R Hoffman
Journal:  Clin Rev Allergy Immunol       Date:  2006-04       Impact factor: 8.667

Review 2.  Chinese Society of Allergy Guidelines for Diagnosis and Treatment of Allergic Rhinitis.

Authors:  Lei Cheng; Jianjun Chen; Qingling Fu; Shaoheng He; Huabin Li; Zheng Liu; Guolin Tan; Zezhang Tao; Dehui Wang; Weiping Wen; Rui Xu; Yu Xu; Qintai Yang; Chonghua Zhang; Gehua Zhang; Ruxin Zhang; Yuan Zhang; Bing Zhou; Dongdong Zhu; Luquan Chen; Xinyan Cui; Yuqin Deng; Zhiqiang Guo; Zhenxiao Huang; Zizhen Huang; Houyong Li; Jingyun Li; Wenting Li; Yanqing Li; Lin Xi; Hongfei Lou; Meiping Lu; Yuhui Ouyang; Wendan Shi; Xiaoyao Tao; Huiqin Tian; Chengshuo Wang; Min Wang; Nan Wang; Xiangdong Wang; Hui Xie; Shaoqing Yu; Renwu Zhao; Ming Zheng; Han Zhou; Luping Zhu; Luo Zhang
Journal:  Allergy Asthma Immunol Res       Date:  2018-07       Impact factor: 5.764

Review 3.  Adjuvants for allergy immunotherapeutics.

Authors:  Carlos Gamazo; Carmen D'Amelio; Gabriel Gastaminza; Marta Ferrer; Juan M Irache
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

Review 4.  Recombinant Allergens in Structural Biology, Diagnosis, and Immunotherapy.

Authors:  Angelika Tscheppe; Heimo Breiteneder
Journal:  Int Arch Allergy Immunol       Date:  2017-05-04       Impact factor: 2.749

5.  Alteration of the tertiary structure of the major bee venom allergen Api m 1 by multiple mutations is concomitant with low IgE reactivity.

Authors:  Cécile Buhot; Alexandre Chenal; Alain Sanson; Sandra Pouvelle-Moratille; Michael H Gelb; André Ménez; Daniel Gillet; Bernard Maillère
Journal:  Protein Sci       Date:  2004-09-30       Impact factor: 6.725

6.  Comprehensive 3D-modeling of allergenic proteins and amino acid composition of potential conformational IgE epitopes.

Authors:  Numan Oezguen; Bin Zhou; Surendra S Negi; Ovidiu Ivanciuc; Catherine H Schein; Gilles Labesse; Werner Braun
Journal:  Mol Immunol       Date:  2008-07-14       Impact factor: 4.407

Review 7.  Modified Allergens for Immunotherapy.

Authors:  Pattraporn Satitsuksanoa; Anna Głobińska; Kirstin Jansen; Willem van de Veen; Mübeccel Akdis
Journal:  Curr Allergy Asthma Rep       Date:  2018-02-16       Impact factor: 4.806

Review 8.  Chinese Guideline on allergen immunotherapy for allergic rhinitis.

Authors:  Yixiao Bao; Jianjun Chen; Lei Cheng; Yinshi Guo; Suling Hong; Weijia Kong; He Lai; Houyong Li; Huabin Li; Jing Li; Tianying Li; Xiaoping Lin; Shixi Liu; Zheng Liu; Hongfei Lou; Juan Meng; Qianhui Qiu; Kunling Shen; Wei Tang; Zezhang Tao; Chengshuo Wang; Xiangdong Wang; Qingyu Wei; Li Xiang; Hua Xie; Yu Xu; Gehua Zhang; Yuan Zhang; Yiwu Zheng; Yuxiang Zhi; Dehua Chen; Haiyu Hong; Quansheng Li; Lin Liu; Yifan Meng; Nan Wang; Yihui Wang; Yue Zhou; Luo Zhang
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

Review 9.  Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives.

Authors:  Birgit Linhart; Rudolf Valenta
Journal:  Vaccine       Date:  2011-11-17       Impact factor: 3.641

10.  Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination.

Authors:  Susanne Vrtala; Monika Fohr; Raffaela Campana; Christian Baumgartner; Peter Valent; Rudolf Valenta
Journal:  Vaccine       Date:  2011-01-05       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.